MDD

This pilot study tests whether a gentle, at-home brain stimulation device (tDCS) can help people with depression maintain their improvement after successful hospital treatments like esketamine, rTMS, or ECT. Thirty adults who have already improved will use the device for 30 minut…

This study tests whether a single 25 mg dose of psilocybin can reduce major depression in 100 adults with cancer, compared to a very low 1 mg dose. Participants must be 20-80 years old, have a current depressive episode, and be at least one month past their cancer diagnosis. The …

This study is testing whether combining psilocybin (the active ingredient in magic mushrooms) with a type of brain stimulation called aiTBS is safe and helpful for people with depression that hasn't improved with other treatments. About 100 adults aged 22-65 with treatment-resist…

This study tests whether taking omega-3 (EPA) supplements for 12 weeks can reduce depressive symptoms in overweight or obese adults with depression and low omega-3 levels. 50 participants will receive either EPA or a placebo. The goal is to see if improving omega-3 status helps m…

This study looks at how stress and inflammation affect the brains of women with major depressive disorder (MDD) or premenstrual dysphoric disorder (PMDD), compared to healthy women. Researchers will use brain scans, stress tests, and blood samples to find differences that could i…

This study is watching 100 adults with major depression who are already receiving TMS therapy as part of their regular care. Researchers want to see if brain scans and symptom changes can predict who will respond well to TMS. The goal is to better understand how depression sympto…